readthroughSign in
Sep 30, 2026Weekly roundupUpdated

Roche posts IMpower010 results in resected NSCLC; adds polatuzumab real-world study

Roche reported long-awaited IMpower010 results in early lung cancer and posted a new real-world polatuzumab registry, alongside prior IMvigor011, forimtamig, afimkibart and petrelintide items.

Roche's latest postings are led by results from its Phase III IMpower010 trial in early-stage lung cancer, with a new real-world lymphoma registry also added to the mix.

  • IMpower010, a Phase III trial comparing atezolizumab with best supportive care following adjuvant cisplatin-based chemotherapy in resected Stage IB-IIIA non-small cell lung cancer, posted results. The trial enrolled 1280 participants.1 Its primary outcome was disease-free survival in the intent-to-treat population, defined as time from randomization to first recurrence, new primary NSCLC, or death.1 Overall status is completed, with study completion actual as of 2026-08-26.1
  • A real-world observational study of polatuzumab vedotin (Polivy) in Chinese adults with diffuse large B-cell lymphoma (NCT05954910) had its record updated, remaining active not recruiting. The study is assessing progression-free survival among Chinese DLBCL participants treated with polatuzumab in real-world settings.2 Enrollment is estimated at 1000 participants, observed across three cohorts based on fitness and prior treatment status.2
  • IMvigor011, a Phase III trial testing atezolizumab against placebo after cystectomy in ctDNA-positive muscle-invasive bladder cancer, posted results. The study is designed to evaluate adjuvant atezolizumab versus placebo in participants who are ctDNA positive and at high risk for recurrence following cystectomy.3 The trial enrolled 761 participants.3 Collaborator Natera, Inc. is listed, with its Signatera assay used for ctDNA monitoring.3
  • A Phase Ib/II trial of forimtamig combinations in relapsed or refractory multiple myeloma (NCT06055075) posted results after being terminated. The study was terminated prematurely because the sponsor decided not to pursue the development of forimtamig.4 Enrollment reached 21 participants.4
  • AMETRINE-SC (NCT07846683), a Phase III trial of subcutaneous afimkibart induction therapy for moderately to severely active ulcerative colitis, remains registered as not yet recruiting. Enrollment is estimated at 350 participants.5 Chugai Pharmaceutical and Pfizer are listed as collaborators.5
  • ZUPREME-3, ZUPREME-4 and ZUPREME-5 (NCT07843498, NCT07843485, NCT07843472), Phase III trials of once-weekly petrelintide versus placebo for weight management across populations with and without Type 2 Diabetes and with established cardiovascular disease, remain registered as not yet recruiting. ZUPREME-3 has an estimated enrollment of 3900 participants.6 ZUPREME-4 has an estimated enrollment of 600 participants.7 ZUPREME-5 has an estimated enrollment of 2500 participants.8 Zealand Pharma is listed as a collaborator on all three.
  • SONATA-MS (NCT07827586), a non-interventional study of subcutaneous ocrelizumab (Ocrevus) in relapsing-remitting multiple sclerosis, remains recruiting. Treatment-naive participants initiating ocrelizumab s.c. will be observed for 12 months to characterize satisfaction following initiation.9 Enrollment is estimated at 1800 participants.9

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.